Skip to content

High risk of anal cancer found in young Latino and Black men with HIV

HAART reduces risk of death or new AIDS in HIV patients with TB

Abacavir/3TC once daily pill gets scientific approval as Kivexa in Europe

Higher immune system activation prior to seroconversion leads to faster CD4 T-cell loss

TB rates and mortality similar in HIV-1 and HIV-2 infected patients

Injecting users may need to start treatment earlier than other HIV+ people, US study reports

HAART alone is not enough for treatment of moderate-severe KS

Isoniazid prophylaxis treatment for children with HIV: is it ready for implementation?

New, accurate TB test approved for use in Europe